Summary of study ST000048

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000046. The data can be accessed directly via it's Project DOI: 10.21228/M84S36 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data (Contains raw data)
Study IDST000048
Study TitleMetabolomic & lipidomic profiles in response to exogenous insulin & GLP-1 infusions during prolonged fasting (GCMS)
Study TypeTimecourse
Study SummaryThis application requests funding to access state-of-the-art metabolomics and lipidomic platforms at the NIH West Coast Metabolomics Center to analyze plasma samples from recent insulin and glucagon-like peptide-1 (GLP-1) infusion experiments performed in prolong-fasted elephant seals. This suite of studies was designed to better assess the mechanisms contributing to the onset of an insulin resistantlike condition induced by prolonged food deprivation/starvation in mammals. Because elephant seals have evolved robust physiological mechanisms that have allowed them to naturally tolerate such protracted bouts of fasting, they provide an ideal model to address our central hypothesis that increased lipid utilization late in the fast contributes to insulin resistance in elephant seals. Insulin resistance is a common consequence of fasting in mammals and, while the mechanisms by which it manifests are still unclear, a metabolic shift favoring increased mobilization and utilization of lipids during prolonged food deprivation may be a principal causative factor. Insulin resistance has a negative connotation due to its association with obesity and diabetes among humans, but it has been suggested to be an adaptive response to food deprivation.
Institute
University of California, Davis
DepartmentGBSF
LaboratoryWCMC Metabolomics Core
Last NameFiehn
First NameOliver
Address451 Health Sci Drive, Davis, CA 95616
Emailofiehn@ucdavis.edu
Phone1-530-752-8258
Submit Date2014-03-25
Num Groups5
Total Subjects117
Study Comments5 general classes are designed in the experiment:
#1 - A=No GLP1/ Late GTT
#2 - B=GLP1 (Low Dose)
#3 - C=GLP1 (High Dose)
#4 - IL- Early Fasting Insulin Infusion
#5 - IE- Late Fasting Insulin Infusion
Each of the 5 classes has 6 timepoints (5x6):
T1 - 0 min
T2 - 10 min
T3 - 30 min
T4 - 60 min
T5 - 120 min
Each timepoint had 5 animals (5 animals x 5 classes x 6 timepoints = 150 total
Because certain animals and timepoints had to be excluded 108 measurments remain.
The experiment also contains 9 technical replicates of pooled samples (pool)
The total sample number is 108 (biological) + 9 pooled samples = 117
Raw Data AvailableYes
Raw Data File Type(s).cdf, .peG,.txt
Uploaded File Size1.8 G
Analysis Type DetailGC-MS
Release Date2014-04-24
Release Version1
Oliver Fiehn Oliver Fiehn
https://dx.doi.org/10.21228/M84S36
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000046
Project DOI:doi: 10.21228/M84S36
Project Title:Metabolomic & lipidomic profiles in response to exogenous insulin & GLP-1 infusions during prolonged fasting
Project Type:Timecourse
Project Summary:This application requests funding to access state-of-the-art metabolomics and lipidomic platforms at the NIH West Coast Metabolomics Center to analyze plasma samples from recent insulin and glucagon-like peptide-1 (GLP-1) infusion experiments performed in prolong-fasted elephant seals. This suite of studies was designed to better assess the mechanisms contributing to the onset of an insulin resistantlike condition induced by prolonged food deprivation/starvation in mammals. Because elephant seals have evolved robust physiological mechanisms that have allowed them to naturally tolerate such protracted bouts of fasting, they provide an ideal model to address our central hypothesis that increased lipid utilization late in the fast contributes to insulin resistance in elephant seals. Insulin resistance is a common consequence of fasting in mammals and, while the mechanisms by which it manifests are still unclear, a metabolic shift favoring increased mobilization and utilization of lipids during prolonged food deprivation may be a principal causative factor. Insulin resistance has a negative connotation due to its association with obesity and diabetes among humans, but it has been suggested to be an adaptive response to food deprivation.
Institute:University of California, Merced
Department:School of Natural Sciences
Laboratory:Molecular and Cellular Biology, Natural Sciences
Last Name:Ortiz
First Name:Rudy
Address:5200 N. Lake Rd.; Merced, CA 95343
Email:rortiz@ucmerced.edu
Phone:209.228.2964

Subject:

Subject ID:SU000066
Subject Type:Animal
Subject Species:Mirounga angustirostris
Taxonomy ID:9716
Species Group:Mammal

Factors:

Subject type: Animal; Subject species: Mirounga angustirostris (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Minutes
SA002026IL04-0Early Fasting Insulin Infusion 0
SA002027IL03-0Early Fasting Insulin Infusion 0
SA002028IL01-0Early Fasting Insulin Infusion 0
SA002029IL05-0Early Fasting Insulin Infusion 0
SA002030IL02-0Early Fasting Insulin Infusion 0
SA002031IL03-10Early Fasting Insulin Infusion 10
SA002032IL02-10Early Fasting Insulin Infusion 10
SA002033IL05-10Early Fasting Insulin Infusion 10
SA002034IL01-10Early Fasting Insulin Infusion 10
SA002035IL04-10Early Fasting Insulin Infusion 10
SA002036IL04-120Early Fasting Insulin Infusion 120
SA002037IL05-120Early Fasting Insulin Infusion 120
SA002038IL03-120Early Fasting Insulin Infusion 120
SA002039IL01-120Early Fasting Insulin Infusion 120
SA002040IL02-120Early Fasting Insulin Infusion 120
SA002041IL05-30Early Fasting Insulin Infusion 30
SA002042IL01-30Early Fasting Insulin Infusion 30
SA002043IL03-30Early Fasting Insulin Infusion 30
SA002044IL04-30Early Fasting Insulin Infusion 30
SA002045IL02-30Early Fasting Insulin Infusion 30
SA002046IL03-60Early Fasting Insulin Infusion 60
SA002047IL04-60Early Fasting Insulin Infusion 60
SA002048IL02-60Early Fasting Insulin Infusion 60
SA002049IL01-60Early Fasting Insulin Infusion 60
SA002050C03-0GLP1 (High Dose) 0
SA002051C02-0GLP1 (High Dose) 0
SA002052C04-0GLP1 (High Dose) 0
SA002053C01-0GLP1 (High Dose) 0
SA002054C04-10GLP1 (High Dose) 10
SA002055C02-10GLP1 (High Dose) 10
SA002056C03-10GLP1 (High Dose) 10
SA002057C01-10GLP1 (High Dose) 10
SA002058C02-120GLP1 (High Dose) 120
SA002059C04-120GLP1 (High Dose) 120
SA002060C03-120GLP1 (High Dose) 120
SA002061C01-120GLP1 (High Dose) 120
SA002062C02-30GLP1 (High Dose) 30
SA002063C03-30GLP1 (High Dose) 30
SA002064C01-30GLP1 (High Dose) 30
SA002065C04-30GLP1 (High Dose) 30
SA002066C01-60GLP1 (High Dose) 60
SA002067C02-60GLP1 (High Dose) 60
SA002068C03-60GLP1 (High Dose) 60
SA002069C04-60GLP1 (High Dose) 60
SA002070B02-0GLP1 (Low Dose) 0
SA002071B01-0GLP1 (Low Dose) 0
SA002072B03-0GLP1 (Low Dose) 0
SA002073B01-10GLP1 (Low Dose) 10
SA002074B03-10GLP1 (Low Dose) 10
SA002075B02-10GLP1 (Low Dose) 10
SA002076B01-120GLP1 (Low Dose) 120
SA002077B02-120GLP1 (Low Dose) 120
SA002078B03-120GLP1 (Low Dose) 120
SA002079B03-30GLP1 (Low Dose) 30
SA002080B01-30GLP1 (Low Dose) 30
SA002081B02-30GLP1 (Low Dose) 30
SA002082B02-60GLP1 (Low Dose) 60
SA002083B03-60GLP1 (Low Dose) 60
SA002084B01-60GLP1 (Low Dose) 60
SA002085IE05-0Late Fasting Insulin Infusion 0
SA002086IE03-0Late Fasting Insulin Infusion 0
SA002087IE02-0Late Fasting Insulin Infusion 0
SA002088IE01-0Late Fasting Insulin Infusion 0
SA002089IE04-0Late Fasting Insulin Infusion 0
SA002090IE03-10Late Fasting Insulin Infusion 10
SA002091IE04-10Late Fasting Insulin Infusion 10
SA002092IE01-10Late Fasting Insulin Infusion 10
SA002093IE05-10Late Fasting Insulin Infusion 10
SA002094IE02-10Late Fasting Insulin Infusion 10
SA002095IE04-120Late Fasting Insulin Infusion 120
SA002096IE05-120Late Fasting Insulin Infusion 120
SA002097IE03-120Late Fasting Insulin Infusion 120
SA002098IE01-120Late Fasting Insulin Infusion 120
SA002099IE02-120Late Fasting Insulin Infusion 120
SA002100IE05-30Late Fasting Insulin Infusion 30
SA002101IE04-30Late Fasting Insulin Infusion 30
SA002102IE02-30Late Fasting Insulin Infusion 30
SA002103IE01-30Late Fasting Insulin Infusion 30
SA002104IE03-30Late Fasting Insulin Infusion 30
SA002105IE03-60Late Fasting Insulin Infusion 60
SA002106IE02-60Late Fasting Insulin Infusion 60
SA002107IE01-60Late Fasting Insulin Infusion 60
SA002108IE04-60Late Fasting Insulin Infusion 60
SA002109A05-0No GLP1/Late GTT 0
SA002110A02-0No GLP1/Late GTT 0
SA002111A03-0No GLP1/Late GTT 0
SA002112A01-0No GLP1/Late GTT 0
SA002113A04-0No GLP1/Late GTT 0
SA002114A03-10No GLP1/Late GTT 10
SA002115A04-10No GLP1/Late GTT 10
SA002116A01-10No GLP1/Late GTT 10
SA002117A05-10No GLP1/Late GTT 10
SA002118A02-10No GLP1/Late GTT 10
SA002119A01-120No GLP1/Late GTT 120
SA002120A02-120No GLP1/Late GTT 120
SA002121A03-120No GLP1/Late GTT 120
SA002122A05-120No GLP1/Late GTT 120
SA002123A04-120No GLP1/Late GTT 120
SA002124A03-30No GLP1/Late GTT 30
SA002125A01-30No GLP1/Late GTT 30
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 117

Collection:

Collection ID:CO000049
Sample Type:Blood

Treatment:

Treatment ID:TR000067

Sample Preparation:

Sampleprep ID:SP000062
Sampleprep Protocol Filename:SOP_Extraction_of_Blood_Samples.pdf
SOP_Derivatization_of_Samples-Standards_2.pdf
Processing Method:Homogenization, protein precipitation via extraction, Solvent Removal w/ Speed Vac
Processing Storage Conditions:On Ice
Extraction Method:3:3:2 Acetonitrile/Isopropanol/Water
Extract Concentration Dilution:30uL of plasma/ml
Extract Cleanup:1:1 Acetonitrile/Water
Extract Storage:-20C Freezer
Sample Derivatization:10ul of 40mg/ml MeOX in pyridine, 91ul of MSTFA +FAMEs mixture
Sample Spiking:FAMEs

Combined analysis:

Analysis ID AN000084
Analysis type MS
Chromatography type GC
Chromatography system Agilent 6890N
Column Restek corporation Rtx-5Sil MS
MS Type EI
MS instrument type GC-TOF
MS instrument name Leco Pegasus III GC TOF
Ion Mode POSITIVE
Units Peak Area

Chromatography:

Chromatography ID:CH000053
Methods Filename:SOP_GCTOF11082012.pdf
Instrument Name:Agilent 6890N
Column Name:Restek corporation Rtx-5Sil MS
Column Temperature:50-330oC
Flow Rate:1ml/min
Injection Temperature:50C ramped to 250C by 12C s-1
Sample Injection:0.5uL
Oven Temperature:50C for 1 min, then ramped at 20C min-1 to 330C, held constant for 5 min
Transferline Temperature:230C
Washing Buffer:Ethyl Acetate
Sample Loop Size:30 m length x 0.25 mm internal diameter
Randomization Order:Excel generated
Chromatography Type:GC

MS:

MS ID:MS000065
Analysis ID:AN000084
Instrument Name:Leco Pegasus III GC TOF
Instrument Type:GC-TOF
MS Type:EI
Ion Mode:POSITIVE
Ion Source Temperature:250°C
Ionization Energy:-70eV
Mass Accuracy:Nominal
Source Temperature:250°C
Scanning Range:80-500 Da
  logo